Abstracts Papers

Cancer and Metabolism
A Strategically Designed Small Molecule Attacks Alpha-ketoglutarate Dehydrogenase in Tumor Cells Through a Redox Process
Learn More »

Lipoate Derivatives as Chemotherapeutic Agents
Lipoic Acid and Lipoic Acid Analogs in Cancer Metabolism and Chemotherapy.

Learn More »

ASH 2016
Phase I study of CPI-613 in combination with Bendamustine for relapsed and refractory T cell lymphoma

Learn More »

ASH 2016
TCA Cycle Inhibition by CPI-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Learn More »

ESMO 2016
CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer

Learn More »

Gastrointestinal Cancers Symposium 2016
The Mitochondrial Metabolism inhibitor CPI-613 in combination with mFOLFIRINOX for pancreatic cancer.

Learn More »

ASCO 2015
The Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in High Risk Relapsed or Refractory AML.

Learn More » 

ASH 2015
The Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML).
Learn More »

ASCO 2014
Poster – A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
Learn More »

ASCO: 2013
Poster: A Phase I Study of the First in Class Mitochondrial Metabolism Inhibitor CPI-613 in Patients with Advanced Hematologic Malignancies
Learn More »

ASCO: 2012
Poster: Translational Assessment of the Efficacy of CPI-613 Against Pancreatic Cancer in Animal Models Vs. Patients With Stage IV Disease
Learn More »

ASCO: 2012
Poster: Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies
Learn More »

AACR: 2012
Poster: Lipoic acid analogs induces ROS, leading to potent mitochondrial enzyme inhibition, metabolic dysfunction and cell death in tumor cells
Learn More »

AACR: 2012
Poster: Regulation of Pancreatic, Gliosarcoma, and Non-Small Lung Cancer via CPI-613, a Novel Selective Anticancer Therapeutic Agent
Learn More »

ASH: 2011
Poster: Altered Lipid and Mitochondrial Metabolism are viable Targets in Acute Leukemia
Learn More »

AACR Metabolism and Cancer: October 2011
Poster: Potent anti-cancer agents, non-redox-active lipoate derivatives, have pervasive, catastrophic regulatory effects on cancer cell metabolism
Learn More »

The Journal of Molecular Medicine: August 2011
Paper: Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo
Learn More »

Case Study and Case Report: 2011
Case study: Long-Term Stable Disease of Stage IV Pancreatic Neuroendocrine Tumors and Without Significant Adverse Effect by CPI-613, an Investigational Novel Anti-Cancer Agent
Learn More »